Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer
文献类型：期刊论文
| 作者 | Yang, Rulei2,3,4; Liu, Yiran1; Yang, Ning1; Zhang, Tian1; Hou, Jiazhen1; He, Zongyan1; Wang, Yutong1; Sun, Xujie1,3; Shen, Jingshan3,4 ; Jiang, Hualiang1,3,4
|
| 刊名 | PHARMACEUTICS
 |
| 出版日期 | 2024-04-01 |
| 卷号 | 16期号:4页码:18 |
| 关键词 | colorectal cancer plant-derived miR159 irinotecan lipid nanoparticle |
| DOI | 10.3390/pharmaceutics16040570 |
| 通讯作者 | Xie, Yuanchao(xieyuanchao@lglab.ac.cn) ; Lang, Tianqun(langtq@lglab.ac.cn) |
| 英文摘要 | Colorectal cancer (CRC) ranks as the third most prevalent global malignancy, marked by significant metastasis and post-surgical recurrence, posing formidable challenges to treatment efficacy. The integration of oligonucleotides with chemotherapeutic drugs emerges as a promising strategy for synergistic CRC therapy. The nanoformulation, lipid nanoparticle (LNP), presents the capability to achieve co-delivery of oligonucleotides and chemotherapeutic drugs for cancer therapy. In this study, we constructed lipid nanoparticles, termed as LNP-I-V by microfluidics to co-deliver oligonucleotides miR159 mimics (VDX05001SI) and irinotecan (IRT), demonstrating effective treatment of CRC both in vitro and in vivo. The LNP-I-V exhibited a particle size of 118.67 +/- 1.27 nm, ensuring excellent stability and targeting delivery to tumor tissues, where it was internalized and escaped from the endosome with a pH-sensitive profile. Ultimately, LNP-I-V significantly inhibited CRC growth, extended the survival of tumor-bearing mice, and displayed favorable safety profiles. Thus, LNP-I-V held promise as an innovative platform to combine gene therapy and chemotherapy for improving CRC treatment. |
| WOS关键词 | CO-DELIVERY ; MESSENGER-RNA ; SIRNA |
| 资助项目 | Lingang Laboratory |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001210058000001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/310992]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xie, Yuanchao; Lang, Tianqun |
| 作者单位 | 1.Lingang Lab, Shanghai 200031, Peoples R China 2.Vigonvita Life Sci Co Ltd, Suzhou 215125, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Rulei,Liu, Yiran,Yang, Ning,et al. Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer[J]. PHARMACEUTICS,2024,16(4):18. |
| APA | Yang, Rulei.,Liu, Yiran.,Yang, Ning.,Zhang, Tian.,Hou, Jiazhen.,...&Lang, Tianqun.(2024).Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer.PHARMACEUTICS,16(4),18. |
| MLA | Yang, Rulei,et al."Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer".PHARMACEUTICS 16.4(2024):18. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。